# A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer

Source: https://onco.cc/trials/nct06840002/  
OnCo record `nct06840002` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Trastuzumab rezetecan, Carboplatin, Bevacizumab in ovarian cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.

## Summary

A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer is a phase 1/2 interventional study registered as NCT06840002 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 150 participants planned, started 2025-03-18 and due to reach its primary completion in 2026-12. Interventions recorded: SHR-A1811, Carboplatin, Bevacizumab, Oxaliplatin for Injection, Paclitaxel injection. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06840002
- Phase: 1/2
- Setting: An Open, Multicenter Phase Ib / II Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
- Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT06840002: https://clinicaltrials.gov/study/NCT06840002

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06840002.json